학술논문
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021.
Document Type
Article
Author
Oliver, Sara E.; Wallace, Megan; See, Isaac; Mbaeyi, Sarah; Godfrey, Monica; Hadler, Stephen C.; Jatlaoui, Tara C.; Twentyman, Evelyn; Hughes, Michelle M.; Rao, Agam K.; Fiore, Anthony; Su, John R.; Broder, Karen R.; Shimabukuro, Tom; Lale, Allison; Shay, David K.; Markowitz, Lauri E.; Wharton, Melinda; Bell, Beth P.; Brooks, Oliver
Source
Subject
*COVID-19 vaccines
*MESSENGER RNA
*THROMBOSIS risk factors
*VACCINE effectiveness
*
*
*
Language
ISSN
0149-2195
Abstract
The article discusses a study on the use of the Janssen (Johnson & Johnson) COVID-19 vaccine conducted by the Advisory Committee on Immunization Practices (ACIP) in the United States.It mentions that after evaluating data on thrombosis with thrombocytopenia syndrome (TTS) and updated benefit-risk assessments, ACIP recommended the preferential use of mRNA COVID-19 vaccines over the Janssen vaccine for all persons aged 18 years and older.